Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
Persons living with HIV (PLWH) receiving tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) risk suffering TDF-associated nephrotoxicity (TDFAN). TDFAN can result in short- and long-term morbidity, including permanent loss of kidney function, chronic kidney disease (CKD), and end...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f586360119f746068b59a260c0962570 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f586360119f746068b59a260c0962570 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f586360119f746068b59a260c09625702021-12-02T20:05:05ZPrognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.1932-620310.1371/journal.pone.0252768https://doaj.org/article/f586360119f746068b59a260c09625702021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252768https://doaj.org/toc/1932-6203Persons living with HIV (PLWH) receiving tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) risk suffering TDF-associated nephrotoxicity (TDFAN). TDFAN can result in short- and long-term morbidity, including permanent loss of kidney function, chronic kidney disease (CKD), and end-stage kidney disease (ESKD) requiring dialysis. Currently, there is no model to predict this risk or discern which patients to initiate TDF-based therapy. Consequently, some patients suffer TDFAN within the first few months of initiating therapy before switching to another suitable antiretroviral or a lower dose of TDF. In a prospective observational cohort study of adult Zambian PLWH, we modelled the risk for TDFAN before initiating therapy to identify individuals at high risk for experiencing AKI after initiating TDF-based therapy. We enrolled 205 HIV-positive, ART-naïve adults initiating TDF-based therapy followed for a median of 3.4 months for TDFAN at the Adult Infectious Disease Research Centre (AIDC) in Lusaka, Zambia. We defined TDFAN as meeting any of these acute kidney disease (AKD) criteria: 1) An episode of estimated glomerular filtration rate (eGFR)< 60ml/ min/1.73m2 within 3 months, 2) reduced eGFR by> 35% within 3 months or 3) increased serum creatinine by> 50% within 3 months. A total of 45 participants (22%) developed acute kidney disease (AKD) after TDF-based therapy. The development of AKD within the first 3 months of commencing TDF-based therapy was associated with an increase in baseline serum creatinine, age, baseline eGFR and female sex. We concluded that baseline characteristics and baseline renal function biomarkers predicted the risk for AKD within the first 3-months of TDF-based therapy.Freeman W ChabalaEdward D SiewWilbroad MutaleLloyd MulengaAggrey MweembaFastone GomaNjeleka BandaPatrick KaongaWilliam C WesterDouglas C HeimburgerMuktar H AliyuDerick MunkombwePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0252768 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Freeman W Chabala Edward D Siew Wilbroad Mutale Lloyd Mulenga Aggrey Mweemba Fastone Goma Njeleka Banda Patrick Kaonga William C Wester Douglas C Heimburger Muktar H Aliyu Derick Munkombwe Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy. |
| description |
Persons living with HIV (PLWH) receiving tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) risk suffering TDF-associated nephrotoxicity (TDFAN). TDFAN can result in short- and long-term morbidity, including permanent loss of kidney function, chronic kidney disease (CKD), and end-stage kidney disease (ESKD) requiring dialysis. Currently, there is no model to predict this risk or discern which patients to initiate TDF-based therapy. Consequently, some patients suffer TDFAN within the first few months of initiating therapy before switching to another suitable antiretroviral or a lower dose of TDF. In a prospective observational cohort study of adult Zambian PLWH, we modelled the risk for TDFAN before initiating therapy to identify individuals at high risk for experiencing AKI after initiating TDF-based therapy. We enrolled 205 HIV-positive, ART-naïve adults initiating TDF-based therapy followed for a median of 3.4 months for TDFAN at the Adult Infectious Disease Research Centre (AIDC) in Lusaka, Zambia. We defined TDFAN as meeting any of these acute kidney disease (AKD) criteria: 1) An episode of estimated glomerular filtration rate (eGFR)< 60ml/ min/1.73m2 within 3 months, 2) reduced eGFR by> 35% within 3 months or 3) increased serum creatinine by> 50% within 3 months. A total of 45 participants (22%) developed acute kidney disease (AKD) after TDF-based therapy. The development of AKD within the first 3 months of commencing TDF-based therapy was associated with an increase in baseline serum creatinine, age, baseline eGFR and female sex. We concluded that baseline characteristics and baseline renal function biomarkers predicted the risk for AKD within the first 3-months of TDF-based therapy. |
| format |
article |
| author |
Freeman W Chabala Edward D Siew Wilbroad Mutale Lloyd Mulenga Aggrey Mweemba Fastone Goma Njeleka Banda Patrick Kaonga William C Wester Douglas C Heimburger Muktar H Aliyu Derick Munkombwe |
| author_facet |
Freeman W Chabala Edward D Siew Wilbroad Mutale Lloyd Mulenga Aggrey Mweemba Fastone Goma Njeleka Banda Patrick Kaonga William C Wester Douglas C Heimburger Muktar H Aliyu Derick Munkombwe |
| author_sort |
Freeman W Chabala |
| title |
Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy. |
| title_short |
Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy. |
| title_full |
Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy. |
| title_fullStr |
Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy. |
| title_full_unstemmed |
Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy. |
| title_sort |
prognostic model for nephrotoxicity among hiv-positive zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/f586360119f746068b59a260c0962570 |
| work_keys_str_mv |
AT freemanwchabala prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT edwarddsiew prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT wilbroadmutale prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT lloydmulenga prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT aggreymweemba prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT fastonegoma prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT njelekabanda prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT patrickkaonga prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT williamcwester prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT douglascheimburger prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT muktarhaliyu prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy AT derickmunkombwe prognosticmodelfornephrotoxicityamonghivpositivezambianadultsreceivingtenofovirdisoproxilfumaratebasedantiretroviraltherapy |
| _version_ |
1718375518752997376 |